Oncotelic Therapeutics, Inc. (OTCQB: OTLC), which owns 45% of the Sapu Nano joint venture, has released new pharmacokinetic and tissue-distribution data demonstrating significant advantages of its intravenous Deciparticle formulation of everolimus, known as Sapu003, over traditional oral administration. The data reveals that oral everolimus dosing leads to extreme gastrointestinal drug accumulation, with stomach tissue levels reaching up to 2,448 times plasma concentrations. In contrast, intravenous Sapu003 limits gastrointestinal tissue exposure to just 36-48 times plasma levels, representing reductions of up to 67-fold.
This substantial reduction in gastrointestinal drug accumulation carries important implications for cancer patients receiving everolimus therapy. The company stated that this shift may improve drug tolerability while maintaining the drug's intrinsic metabolic profile and providing more consistent systemic exposure. Everolimus is commonly used in oncology treatments, particularly for certain kidney cancers, breast cancers, and other malignancies, but its oral administration often leads to significant gastrointestinal side effects that can limit patient compliance and treatment effectiveness.
The improved tissue distribution profile of Sapu003 could potentially enhance the therapeutic window for everolimus-based treatments. By minimizing gastrointestinal exposure while maintaining systemic drug levels, patients might experience fewer dose-limiting toxicities and better overall treatment outcomes. This development is particularly relevant given Oncotelic Therapeutics' focus on addressing high-unmet-need cancers and rare pediatric indications with innovative therapeutic candidates.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company that benefits from the extensive intellectual property portfolio of its CEO, Dr. Vuong Trieu, who has filed more than 150 patent applications and holds 39 issued U.S. patents. The company's strategic position in oncology and rare disease therapeutics is further strengthened through joint ventures like GMP Bio, which advances complementary drug candidates. Additional information about the company's developments is available through their newsroom at https://ibn.fm/OTLC.
The broader implications of this pharmacokinetic advancement extend beyond individual patient benefits to potentially influence treatment protocols and drug development strategies across oncology. As biopharmaceutical companies continue to seek improved formulations of existing therapies, the Sapu003 data demonstrates how alternative delivery methods can significantly alter drug distribution patterns and potentially improve therapeutic indices. This development occurs within the context of increasing attention to drug delivery optimization in cancer treatment, where minimizing off-target effects while maximizing therapeutic benefit remains a critical challenge.
The data release was facilitated through BioMedWire, a specialized communications platform focusing on biotechnology and life sciences developments that is part of the Dynamic Brand Portfolio at IBN. BioMedWire provides distribution services across multiple channels, including wire solutions, editorial syndication to over 5,000 outlets, and social media distribution to millions of followers. More information about their services can be found at https://www.BioMedWire.com, with full terms and disclaimers available at https://www.BioMedWire.com/Disclaimer.
